clinicaltrials.gov
ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days RSS kanalas
Gaukite naujausius ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days atnaujinimus iškart, kai jie pasirodo.
Naujausi įrašai
Skaitykite ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days ten, kur skaitote kitus šaltinius
Žmonės, sekantys ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days, taip pat seka
-
Amylyx Pharmaceuticals, Inc. SEC Filings investors.amylyx.com
-
Alzforum News alzforum.org
-
Search Feed scrip.pharmaintelligence.informa.com
-
-
Eli Lilly and Company SEC Filings investor.lilly.com
-
-
investors.pfizer.com investors.pfizer.com
-
AbbVie Events investors.abbvie.com
Daugiau RSS kanalų, kuriuos galite atrasti
-
ClinicalTrials.gov: Gastric Cancer | Not yet recruiting, Recruiting, Active, not recruiting studies | Phase: 3 | Interventional studies | Funded by Industry | Last update posted in the last 14 days clinicaltrials.gov
-
-
Klausimai
Koks yra ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days RSS kanalo URL?
Kanalo adresas yra https://clinicaltrials.gov/api/rss?cond=Alzheimer+Disease&intr=Lecanemab+OR+donanemab+OR+Remternetug+OR+Trontinemab+OR+Crenezumab+OR+Valitramiprostate&dateField=LastUpdatePostDate. Įklijuokite jį į bet kurią RSS skaityklę arba spustelėkite Sekti dabar, kad skaitytumėte per Feeder.
Kaip dažnai ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days skelbia įrašus?
ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days skelbia įrašus maždaug 4 kartus per savaitę. Paskutinis įrašas paskelbtas prieš apie 11 valandų.
Ar ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days RSS kanalas veikia?
Taip. Feeder patikrino jį prieš 9 minutės, o kanalas atsakė be klaidų.
Kaip sekti ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days per Feeder?
Spustelėkite Sekti dabar ir, jei dar neturite paskyros, užsiregistruokite. Nemokamas Feeder planas apima iki 200 srautų ir veikia žiniatinklyje, iPhone bei Android įrenginiuose. Kredito kortelės nereikia.
Sekite ClinicalTrials.gov: Alzheimer Disease | Lecanemab OR donanemab OR Remternetug OR Trontinemab OR Crenezumab OR Valitramiprostate | Last update posted in the last 14 days per Feeder
Nemokamas Feeder planas apima iki 200 srautų ir veikia žiniatinklyje, iPhone bei Android įrenginiuose. Kredito kortelės nereikia.